Why the study?
It is uncertain whether risks of ischaemic stroke or intracranial haemorrhage differ between potent P2Y12 inhibitors and clopidogrel, particularly in Chinese patients where data are sparse despite East Asians having distinct thrombotic and haemorrhagic profiles.
Do potent P2Y12 inhibitors reduce ischaemic stroke compared to clopidogrel in Chinese patients with ACS undergoing PCI?
Do potent P2Y12 inhibitors reduce ischaemic stroke compared to clopidogrel in Chinese patients with ACS undergoing PCI?
In Chinese patients with ACS undergoing PCI, potent P2Y12 inhibitors were associated with a reduced risk of ischemic stroke and thrombotic events without a significant increase in intracranial hemorrhage or major bleeding compared to clopidogrel.
Answers are grounded in this paper and cite their sources.
Associated with lower ischaemic stroke risk without excess ICH in Chinese post-PCI patients; leaves open need for prospective trials before practice change.
BACKGROUND: Stroke after acute coronary syndrome (ACS) can be devastating. It is uncertain whether the risks of ischaemic stroke or intracranial haemorrhage (ICH) are associated with different choices of P2Y12 inhibitors (potent P2Y12 inhibitors such as ticagrelor and prasugrel vs clopidogrel). Even though East Asians are known to have different thrombotic and haemorrhagic profiles from Caucasians, data on Chinese patients are sparse. METHOD: This was a retrospective cohort study conducting in Chinese patients with ACS who underwent first-ever percutaneous coronary intervention from 14 hospitals in Hong Kong between 2010 and 2017. The primary efficacy endpoint was ischaemic stroke. The secondary efficacy endpoint was a composite outcome of thrombotic events including all-cause mortality, non-fatal myocardial infarction and ischaemic stroke. The primary safety endpoint was ICH. The secondary safety endpoint was a composite of major bleeding events. RESULTS: After adjustment of baseline characteristics by 1:1 propensity score matching, a total of 6220 patients (3110 on each group) were analysed. Compared with clopidogrel, potent P2Y12 inhibitors were associated with a lower risk of ischaemic stroke (HR 0.57; 95% CI 0.37 to 0.87; p=0.008) and a lower risk of thrombotic events (HR 0.77; 95% CI 0.66 to 0.90; p=0.001). Potent P2Y12 inhibitor was associated with similar risk of ICH (HR 0.65; 95% CI 0.34 to 1.25, p=0.20) and major bleeding (HR 0.83; 95% CI 0.68 to 1.01, p=0.069). CONCLUSIONS: Potent P2Y12 inhibitors were associated with a lower adjusted risk of ischaemic stroke and thrombotic events, compared with clopidogrel. The risks of ICH and major bleeding were similar.
No takes yet. Share an insight, caveat, or question.
Ng et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: